Grazia Marsico
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Grazia Marsico has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Abhay Pandit
Cúram Research Ireland Centre for Medical Devices University of Galway Galway Ireland
2 shared publications - Arun Thirumaran
Centre for Research in Medical Devices (CÚRAM), University of Galway, Ireland
1 shared publication - Bartlomiej Lukasz
Conway Institute, University College Dublin, Dublin 4, Ireland
1 shared publication - Brian J. Rodriguez
University College Dublin
1 shared publication - Dilip Thomas
Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA
1 shared publication - Federico Ferro
Department of Medical and Biological Sciences, University of Udine, 33100 Udine, Italy
1 shared publication
Latest Publications
- Open Access
Synthetic Biology and Biomaterials Strategies to Deceive the Tumor Microenvironment in CAR‐T Immunotherapy
Chimeric antigen receptor (CAR)‐T cell immunotherapy has emerged as a groundbreaking approach in cancer treatment, offering new hope across various malignancies. However, its success against solid tumors remains limited due to critical challenges, including off‐tumor, on‐target toxicity, immune resistance, poor T cell infiltration into the tumor microenvironment (TME), and T cell exhaustion. In response, interdisciplinary innovations in synthetic biology and biomaterials are redefining how can be engineer smarter, more responsive CAR‐T cells. Recent advances have introduced biomaterials not only as precision delivery vehicles but also as artificial antigen‐presenting cells (APCs), high‐throughput screening platforms, and tools to replicate the complex biomechanical landscape of the TME. This review highlights these cutting‐edge strategies, emphasizing how biomaterials and synthetic circuits can aid studies and strategies to enhance CAR‐T cell efficacy in solid tumors while minimizing adverse effects. Future directions at the intersection of tumor‐inspired biomaterials and T cell engineering, envisioning a new generation of CAR‐T therapies tailored to overcome the formidable barriers of the TME are also explored.
Open AccessSynthetic Biology and Biomaterials Strategies to Deceive the Tumor Microenvironment in CAR‐T Immunotherapy
Chimeric antigen receptor (CAR)‐T cell immunotherapy has emerged as a groundbreaking approach in cancer treatment, offering new hope across various malignancies. However, its success against solid tumors remains limited due to critical challenges, including off‐tumor, on‐target toxicity, immune resistance, poor T cell infiltration into the tumor microenvironment (TME), and T cell exhaustion. In response, interdisciplinary innovations in synthetic biology and biomaterials are redefining how can be engineer smarter, more responsive CAR‐T cells. Recent advances have introduced biomaterials not only as precision delivery vehicles but also as artificial antigen‐presenting cells (APCs), high‐throughput screening platforms, and tools to replicate the complex biomechanical landscape of the TME. This review highlights these cutting‐edge strategies, emphasizing how biomaterials and synthetic circuits can aid studies and strategies to enhance CAR‐T cell efficacy in solid tumors while minimizing adverse effects. Future directions at the intersection of tumor‐inspired biomaterials and T cell engineering, envisioning a new generation of CAR‐T therapies tailored to overcome the formidable barriers of the TME are also explored.
- Open Access
- 24 July 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (32) , 19033-19044
Temporal changes guided by mesenchymal stem cells on a 3D microgel platform enhance angiogenesis in vivo at a low-cell dose
Therapeutic factors secreted by mesenchymal stem cells (MSCs) promote angiogenesis in vivo. However, delivery of MSCs in the absence of a cytoprotective environment offers limited efficacy due to low cell retention, poor graft survival, and the nonmaintenance of a physiologically relevant dose of growth factors at the injury site. The delivery of stem cells on an extracellular matrix (ECM)-based platform alters cell behavior, including migration, proliferation, and paracrine activity, which are essential for angiogenesis. We demonstrate the biophysical and biochemical effects of preconditioning human MSCs (hMSCs) for 96 h on a three-dimensional (3D) ECM-based microgel platform. By altering the macromolecular concentration surrounding cells in the microgels, the proangiogenic phenotype of hMSCs can be tuned in a controlled manner through cell-driven changes in extracellular stiffness and “outside-in” integrin signaling. The softest microgels were tested at a low cell dose (5 × 104 cells) in a preclinical hindlimb ischemia model showing accelerated formation of new blood vessels with a reduced inflammatory response impeding progression of tissue damage. Molecular analysis revealed that several key mediators of angiogenesis were up-regulated in the low-cell-dose microgel group, providing a mechanistic insight of pathways modulated in vivo. Our research adds to current knowledge in cell-encapsulation strategies by highlighting the importance of preconditioning or priming the capacity of biomaterials through cell–material interactions. Obtaining therapeutic efficacy at a low cell dose in the microgel platform is a promising clinical route that would aid faster tissue repair and reperfusion in “no-option” patients suffering from peripheral arterial diseases, such as critical limb ischemia (CLI). Significance An optimal 3D cell-delivery platform is key for cytoprotection and prolonged cell function in vivo for sustained delivery of therapeutic factors as “cell factories.” However, little is known about stem-cell phenotype and behavior resulting from in vitro preconditioning in engineered extracellular matrices. We demonstrate a close relationship between macromolecular concentration and mesenchymal stem cell behavior that drives morphological changes, modulation of integrin expression, and matrix rigidity after 96 h of in vitro preconditioning. Changes induced by the optimal microenvironment influence a proangiogenic phenotype of mesenchymal stem cells in a concentration-dependent manner and play a key role in promoting angiogenesis in vivo at a 20 times lower cell dose than the preclinical standard, tested in a severe, double-ligation model of CLI.
- 24 July 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (32) , 19033-19044
Open AccessTemporal changes guided by mesenchymal stem cells on a 3D microgel platform enhance angiogenesis in vivo at a low-cell dose
Therapeutic factors secreted by mesenchymal stem cells (MSCs) promote angiogenesis in vivo. However, delivery of MSCs in the absence of a cytoprotective environment offers limited efficacy due to low cell retention, poor graft survival, and the nonmaintenance of a physiologically relevant dose of growth factors at the injury site. The delivery of stem cells on an extracellular matrix (ECM)-based platform alters cell behavior, including migration, proliferation, and paracrine activity, which are essential for angiogenesis. We demonstrate the biophysical and biochemical effects of preconditioning human MSCs (hMSCs) for 96 h on a three-dimensional (3D) ECM-based microgel platform. By altering the macromolecular concentration surrounding cells in the microgels, the proangiogenic phenotype of hMSCs can be tuned in a controlled manner through cell-driven changes in extracellular stiffness and “outside-in” integrin signaling. The softest microgels were tested at a low cell dose (5 × 104 cells) in a preclinical hindlimb ischemia model showing accelerated formation of new blood vessels with a reduced inflammatory response impeding progression of tissue damage. Molecular analysis revealed that several key mediators of angiogenesis were up-regulated in the low-cell-dose microgel group, providing a mechanistic insight of pathways modulated in vivo. Our research adds to current knowledge in cell-encapsulation strategies by highlighting the importance of preconditioning or priming the capacity of biomaterials through cell–material interactions. Obtaining therapeutic efficacy at a low cell dose in the microgel platform is a promising clinical route that would aid faster tissue repair and reperfusion in “no-option” patients suffering from peripheral arterial diseases, such as critical limb ischemia (CLI). Significance An optimal 3D cell-delivery platform is key for cytoprotection and prolonged cell function in vivo for sustained delivery of therapeutic factors as “cell factories.” However, little is known about stem-cell phenotype and behavior resulting from in vitro preconditioning in engineered extracellular matrices. We demonstrate a close relationship between macromolecular concentration and mesenchymal stem cell behavior that drives morphological changes, modulation of integrin expression, and matrix rigidity after 96 h of in vitro preconditioning. Changes induced by the optimal microenvironment influence a proangiogenic phenotype of mesenchymal stem cells in a concentration-dependent manner and play a key role in promoting angiogenesis in vivo at a 20 times lower cell dose than the preclinical standard, tested in a severe, double-ligation model of CLI.
- Open Access
- 1 January 2020
- Published by Elsevier in Materials Today Bio
- Vol. 5, 100040
A worm gel-based 3D model to elucidate the paracrine interaction between multiple myeloma and mesenchymal stem cells
- 1 January 2020
- Published by Elsevier in Materials Today Bio
- Vol. 5, 100040
Open AccessA worm gel-based 3D model to elucidate the paracrine interaction between multiple myeloma and mesenchymal stem cells